Search

For outcomes after auto-HCT, allogeneic transplant (allo-HCT), and chimeric antigen receptor T cell therapy (CAR-T), I TP53 i alteration must have been present at time of this therapy. Event free survival (EFS) after auto-HCT, allo-HCT, and CAR-T was defined as time from treatment to relapse, subsequent therapy, or death. OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI-INSTITUTION RETROSPECTIVE ANALYSIS. [Extracted from the article]

B Results: b Thirty-six patients signed informed consent and were treated, including 10 in the phase I cohort, 10 in the phase Ib HL cohort, and 16 in the phase II LBCL cohort. For the phase 2 LBCL cohort, the median age was 62, 12/16 patients were male, 14/16 had prior CAR-T, and the median prior treatments were 4 (range 2-5). B Introduction: b Lenalidomide (len) and nivolumab (nivo) each have single agent activity in relapsed Hodgkin lymphoma (HL) and large B-cell lymphoma (LBCL) with potential for additive or synergistic activity. [Extracted from the article]

B Introduction: b Patients (pts) with I R i / I R i DLBCL who are not candidates for autologous stem cell transplant (ASCT) or CAR T-cell therapy have limited treatment options. Pts must have received >=2 prior lines of therapy, including an alkylating agent, an anthracycline, and an anti-CD20 antibody, and must have been ineligible for or had disease progression after ASCT and CAR T-cell therapy. The ROR1-targeting antibody-drug conjugate zilovertamab vedotin (ZV) had promising antitumor activity and manageable safety in pts with I R i / I R i DLBCL in the phase 1 waveLINE-001 study. [Extracted from the article]